Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) (GSKCONS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500676 NSE: GSKCONS Consumer Food | Mid Cap | Glaxo.Cons. Health Share Price
₹9,696.40 0.00 (0.00%)
As on 15-Apr'20 18:01
Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) (GSKCONS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 500676 NSE: GSKCONS Consumer Food | Mid Cap | Glaxo.Cons. Health Share Price
₹9,696.40 0.00 (0.00%)
As on 15-Apr'20 18:01
Key Metrics
Valuation Multiples
Market Cap
₹45,225 Cr.
Current Price
₹9,696.4
52-Week Low / High
₹10,394 / 10,846
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
51.8
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
10.78%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
72.46%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹42.1 Cr.
Face Value
₹10
All Time Low / High
₹93.75 / 11290.00
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 43% | 48.7% | 51.7% | 52% | 64.1% | 45.3% | 43% | 34.1% | 32.5% | 39.9% | - |
| Value Creation Index ⓘ | 2.2 | 2.6 | 2.8 | 2.9 | 3.8 | 3.0 | 2.8 | 2.0 | 1.9 | 2.6 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 1,922 | 2,306 | 2,765 | 3,187 | 3,895 | 4,308 | 4,136 | 3,991 | 4,317 | 4,782 | 4,984 |
| Sales YoY Gr. | - | 20% | 19.9% | 15.3% | 22.2% | 10.6% | -4% | -3.5% | 8.2% | 10.8% | - |
| Adj EPS ⓘ | 55.4 | 71.2 | 83.8 | 102.9 | 127.4 | 138.9 | 161.7 | 155.5 | 165.3 | 232.3 | 274.8 |
| YoY Gr. | - | 28.5% | 17.7% | 22.7% | 23.9% | 9% | 16.4% | -3.8% | 6.3% | 40.6% | - |
| BVPS (₹) ⓘ | 215.2 | 228.3 | 272.1 | 323.6 | 344.9 | 502.4 | 665.5 | 742.5 | 828.7 | 973.7 | 1,055.4 |
| Adj Net Profit ⓘ | 233 | 299 | 352 | 433 | 536 | 584 | 680 | 654 | 695 | 977 | 1,156 |
| Cash Flow from Ops. ⓘ | 400 | 326 | 391 | 554 | 516 | 611 | 573 | 603 | 723 | 671 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 10.7% | 4.2% | 5% | 10.8% | ||||
| Adj EPS ⓘ | 17.3% | 12.8% | 12.8% | 40.6% | ||||
| BVPSⓘ | 18.3% | 23.1% | 13.5% | 17.5% | ||||
| Share Price | 4.8% | -2.1% | -3.4% | -9.8% | ||||
Key Financial Parameters ⓘ
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 28 | 32.1 | 33.5 | 34.5 | 42.2 | 29.8 | 27.7 | 22.1 | 21 | 25.8 | 27.1 |
| Op. Profit Mgn % ⓘ | 16.3 | 16.4 | 18.2 | 18 | 18 | 17.2 | 20.3 | 21 | 20.5 | 23.9 | 25.4 |
| Net Profit Mgn % ⓘ | 12.1 | 13 | 12.8 | 13.6 | 13.8 | 13.6 | 16.4 | 16.4 | 16.1 | 20.4 | 23.2 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 178 | 157 | 170 | 118 | 115 | 223 | 250 | 294 | 324 | 332 | 181 |
| Cash Conv. Cycle ⓘ | 3 | -12 | -12 | -14 | -14 | -18 | -33 | -43 | -53 | -50 | 120 |
Valuation of Glaxo.Cons. Health - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) FAQs
The current trading price of Glaxo.Cons. Health on 15-Apr-2020 18:01 is ₹9,696.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 14-Apr-2020 the market cap of Glaxo.Cons. Health stood at ₹45,225.1 Cr
The latest P/E ratio of Glaxo.Cons. Health as of 14-Apr-2020 is 39.13.
The latest P/B ratio of Glaxo.Cons. Health as of 14-Apr-2020 is 10.19.
The 52-week high of Glaxo.Cons. Health is ₹10,845.8 and the 52-week low is ₹10,394.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glaxo.Cons. Health is ₹4,984 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated) is a good quality company.
The key valuation ratios of Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)'s currently when compared to its past seem to suggest it is in the Overvalued zone.
No data found
About Glaxosmithkline Consumer Healthcare Ltd. - (Amalgamated)
Glaxosmithkline Consumer Healthcare’s (GCH) core business is manufacturing of health drinks under the brand Horlicks. The history of the company goes way back in 1950s when bottled Horlicks was imported from
During 1956-57 a team of Horlicks visited
In the year 1969 Beecham plc acquired
In January 2000 the name was changed to Glaxosmithkline Consumer Healthcare.
It exports products to countries like
GCH has manufacturing plants located at Punjab, Andhra Pradesh, Haryana,
Glaxosmithkline Consumer Healthcare has entered into an agreement with Laclede to purchase its dry mouth brand Biotene for $170 million.
In 2011 GSk has launched Sensodyne in an attempt to enter the Indian tooth paste market. "
Products
Nutritional drinks- Under this it manufactures and markets wide range of health drinks. Besides Horlicks, it has created brands like, Boost, Maltova and Viva. Apart from youth, it also caters to other consumers like mothers with Mother’s Horlicks and Horlicks Lite for diabetic consumers.
OTC Products- It promotes and distributes over the counter drugs like pain relief balm -- Iodex, pain relief tablet and syrup -- Crocin and drug for acidity problems -- Eno.
The company’s nutritional food services division has also developed vending of Boost and Horlicks. Around 500 vending machine have been placed in corporates, schools and hospitals.
Award and Recognition
It manufacturing plants have received various certification for its quality and health and safety systems such as OHSAS 18001, ISO 9001:2000 and ISO 14001:2004 by DNV and SA8000.
The company’s Sonepat factory has won the prestigious “National Energy Conservation Award – 2007†from the President of India in the Food Processing Sector.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
